Retrospective Post-Marketing Safety Surveillance Study of Tofacitinib in Psoriatic Arthritis (PsA) and Rheumatoid Arthritis (RA)

21/09/2022
23/04/2024
EU PAS number:
EUPAS46286
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

A3921421 Non-Interventional Protocol Study Version 1.0_ 30 August 2022_Redacted

English (3.1 MB - PDF) View document
Updated protocol

A3921421 Non-Interventional Protocol Study Amendment 1_v2.0_(clean) 07 December 2022_Redacted

First published: 22/02/2024
English (3.23 MB - PDF) View document
Study results
Study results

A3921421 Non-Interventional Study Report Abstract 13 November 2023_Redacted

English (158.26 KB - PDF) View document
Study report
Other information
Study, other information

A3921421 Non Interventional Study Abstract (clean)_v2.0_07Dec2022_Redacted

English (1.72 MB - PDF) View document

A3921421 Non Interventional Study Abstract 30 August 2022_Redacted

English (9.26 MB - PDF) View document

A3921421 Non-Interventional Study Report 13 November 2023_Redacted

English (8.54 MB - PDF) View document